Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Candesartan add-on therapy for heart failure with preserved ejection fraction in diabetic and hypertensive patients
2007-003070-26Phase 3Terminated
- Sponsor
- Takeda
- Start
- Jul 2007
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) and diastolic dysfunction comparing Candesartan cilexetil add-on with Placebo add-on (2 arms). Primary endpoint: Change in NT-proBNP from baseline to final visit. Started Jul 2007; status: terminated.
02
Drugs
candesartan cilexetil
03
Conditions
heart failure with preserved ejection fraction (HFpEF)diastolic dysfunction
Beyond the preview
Go deeper on 2007-003070-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003070-26.